All congress activities

This infographic, which supports the poster presented at GMDI 2026, highlights findings from the APHENITY extension study evaluating the long-term effects of sepiapterin treatment on dietary phenylalanine tolerance in children aged ≤2 years with phenylketonuria (PKU)

This poster, presented at GMDI 2026, highlights findings from the APHENITY extension study evaluating the long-term effects of sepiapterin treatment on dietary phenylalanine tolerance in children aged ≤2 years with phenylketonuria (PKU)

This infographic, which supports the poster presented at SIMD 2026, describes interim results from the Phase 3 APHENITY Extension Study evaluating diet liberalization and health-related quality of life (HRQoL) in sepiapterin-treated individuals with phenylketonuria (PKU) who were receiving sapropterin at study entry

This poster, presented at SIMD 2026, describes interim results from the Phase 3 APHENITY Extension Study evaluating diet liberalization and health-related quality of life (HRQoL) in sepiapterin-treated individuals with phenylketonuria (PKU) who were receiving sapropterin at study entry

This poster, presented at SIMD 2026, highlights interim results from the Phase 3 APHENITY Extension Study evaluating the long-term safety and responsiveness of sepiapterin treatment in children aged ≤2 years with phenylketonuria (PKU)

This poster, presented at ACMG 2025, describes interim results from the ongoing APHENITY extension study, which evaluated the effect of sepiapterin on dietary Phe tolerance in a broad population of phenylketonuria (PKU) participants

This poster, originally given as an oral presentation at ACMG 2026, summarizes results from three Phase 3 clinical trials that assessed sepiapterin responsiveness in patients with phenylketonuria (PKU)

This ICIEM 2025 oral presentation provides an overview of the AMPLIPHY phase 3 study which compares the efficacy and safety of sepiapterin and sapropterin in children and adults with phenylketonuria (PKU)

This symposium, presented at ICIEM 2025, provides an overview of sepiapterin as a treatment for phenylketonuria (PKU) and the current PKU disease landscape

This symposium, presented at ACMG 2025, summarizes the APHENITY study which assessed the effectiveness of sepiapterin on dietary Phe in a broad population of phenylketonuria (PKU) patients, and discusses the need for innovative treatment approaches